We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Kojic Acid (topical)
A topical skin-brightening active applied to the skin for hyperpigmentation and melasma — a cosmetic, not ingested. Kojic acid is a fungal-derived tyrosinase inhibitor (it chelates the copper at the enzyme's active site, slowing melanin production). It has genuine human RCT support for melasma and appears in a large 2023 meta-analysis with a statistically significant effect. The honest framing: the effect size is modest — the weakest of the major depigmenting agents in that meta-analysis — and most of the strong evidence is for kojic acid ADDED to hydroquinone/glycolic-acid bases rather than used alone. Contact sensitisation (allergy) is a well-documented downside of long-term use. These are cosmetic appearance outcomes, not health outcomes.
Topical cosmetic ingredient — not a dietary supplement
Kojic Acid is a topical cosmetic ingredient, not a supplement you take internally and not a drug. It is sold legally in skincare products to affect the appearance of skin (such as wrinkles). The evidence below comes mostly from small, often industry-funded studies of topical application, so treat the effect sizes cautiously. This page is for transparency and education, not a recommendation.
What the evidence says
Most Kojic Acid studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1995–2023 with a typical study size of 80 participants.
Based on 11 studies · 1 meta-analysis · 7 RCTs · 385 total participants
Confidence
Moderate confidenceBy outcome
Genuine human RCT support for melasma and a confirmed tyrosinase-inhibition mechanism, included in a large 2023 meta-analysis with a statistically significant effect — but the effect size is the smallest among major depigmenting agents, the strongest evidence is for kojic acid combined with hydroquinone/glycolic acid rather than monotherapy, and contact sensitisation is a documented risk.
Kojic acid (5-hydroxy-2-(hydroxymethyl)-4-pyranone) is a metabolite produced by Aspergillus and Penicillium fungi, used as a topical skin-lightening active in cosmetics, typically around 1-2% (the more stable kojic acid dipalmitate is also used). This entry covers TOPICAL cosmetic use — it is not ingested.
Mechanistically, kojic acid inhibits tyrosinase, the rate-limiting enzyme of melanogenesis, by chelating the copper ions at its active site; a biochemical comparison found it about ten times more potent than arbutin or hydroquinone in a purified-enzyme assay, though far weaker than 4-n-butylresorcinol and only modestly active in artificial-skin melanin assays.
The clinical evidence is real but modest and largely combination-based. A split-face RCT (Lim, 1999) showed that adding 2% kojic acid to a 10% glycolic acid + 2% hydroquinone gel further improved melasma (60% vs 47.5% achieving clearance).
A four-arm RCT (Deo et al., 2013) found kojic acid combined with hydroquinone was the most effective regimen, with kojic acid monotherapy weaker.
A large 2023 systematic review and meta-analysis (Chang et al.; 45 efficacy studies, 2359 patients) found kojic acid produced a statistically significant MASI reduction — but the smallest effect size among the major agents (standardised mean difference -0.9, versus -1.3 to -1.6 for hydroquinone, cysteamine, tranexamic acid, and azelaic acid) — while having a low skin-irritation rate (5.3%).
The honest counter-evidence: a head-to-head trial (Azzam et al., 2009) found topical hydroquinone + kojic acid underperformed chemical peels for melasma; a pilot (Hermanns et al., 2002) found a 1% kojic acid combination inefficacious on solar lentigines; and crucially, contact allergy is a recognised hazard — a patch-test series (Nakagawa et al., 1995) judged kojic acid to have 'high sensitizing potential,' with users developing facial dermatitis 1-12 months after starting kojic-acid products.
None of this is a health claim: kojic acid is a lawful cosmetic whose documented benefit is a modest improvement in the appearance of hyperpigmentation, best realised in combination with other actives and tempered by a real sensitisation risk.
It is listed under Beauty & Appearance so it is discoverable, but is sandboxed out of ingestible-supplement stacks and the schedule optimizer; it carries a cosmetic badge and a topical-only disclaimer.
Kojic acid chelates the copper ions at the active site of tyrosinase, the rate-limiting enzyme of melanin synthesis, slowing pigment production. In a purified-enzyme assay it was ~10x more potent than arbutin or hydroquinone, but only modestly active in artificial-skin melanin models — consistent with its real-but-modest clinical effect.
Kojic acid has antioxidant activity that may contribute to its effect on UV- and inflammation-driven pigmentation, complementing direct tyrosinase inhibition.
Topical kojic acid has limited safety data in pregnancy and lactation; discuss with a clinician, and consider better-studied alternatives like azelaic acid.
Higher sensitisation risk — patch-test and monitor for delayed contact dermatitis.
Manage expectations — kojic acid is a modest, usually adjunct brightener; hydroquinone, azelaic acid, or clinician-guided combinations have stronger evidence, and daily sunscreen is essential.
Often combined with other brighteners/exfoliants, which can increase irritation; introduce gradually. This is a tolerability/formulation consideration, not a systemic drug interaction — it is not ingested.
Tip: Patch-test first; sensitisation can appear weeks to months in. Discontinue if facial dermatitis develops.
Tip: Reduce frequency or concentration; buffer with moisturizer.
Kojic Acid has an evidence score of 6/10 — moderate evidence based on 11 indexed studies, including 1 meta-analysis. A topical skin-brightening active applied to the skin for hyperpigmentation and melasma — a cosmetic, not ingested. Kojic acid is a fungal-derived tyrosinase inhibitor (it chelates the copper at the enzyme's active site, slowing melanin production). It has genuine human RCT support for melasma and appears in a large 2023 meta-analysis with a statistically significant effect. The honest framing: the effect size is modest — the weakest of the major depigmenting agents in that meta-analysis — and most of the strong evidence is for kojic acid ADDED to hydroquinone/glycolic-acid bases rather than used alone. Contact sensitisation (allergy) is a well-documented downside of long-term use. These are cosmetic appearance outcomes, not health outcomes. Representative study: PMID 36566490.
The commonly studied dose of Kojic Acid is Topical cosmetic only. Kojic acid is typically used at roughly 1-2% in leave-on serums or creams (or as the more stable kojic acid dipalmitate), applied to areas of hyperpigmentation once or twice daily, often alongside other brighteners and daily sunscreen. There is no oral, injectable, or systemic dose — it is not ingested. This library does not provide an ingestion protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Kojic Acid — consistent daily use matters more than the time of day. Kojic acid is a leave-on topical with no meal-timing relationship; pairing with daily sunscreen matters more, since UV drives the pigmentation it targets.
Kojic Acid is generally safe at recommended doses, with a few precautions worth noting. Reported side effects are uncommon and include contact dermatitis / allergic sensitisation, local irritation, redness, or stinging. Use caution if any of these apply to you: For topical (skin) use only — not for ingestion, not for injection; Known allergy or sensitivity to kojic acid; Application to broken, irritated, or compromised skin until healed.
Sunscreen (SPF)
Mostly mechanism / observationalDaily broad-spectrum sunscreen — the single most evidence-based anti-aging skincare step there is, and the one most 'anti-aging' actives are really just trying to compensate for. The honest framing: this is the only topical on this list backed by a proper randomized controlled trial for skin aging itself. In the landmark Hughes 2013 trial (n=903), people randomized to daily sunscreen showed 24% less photoaging over 4.5 years — and no detectable increase in skin aging at all — while the mechanism (UV → matrix-metalloproteinase activation → collagen breakdown) is textbook. The same trial cohort also had less skin cancer. The honest caveats: the benefit is overwhelmingly prevention, not reversal of existing damage; real-world results depend entirely on applying enough and reapplying; and chemical (organic) UV filters are systemically absorbed above an FDA testing threshold (clinical significance unknown — mineral zinc-oxide/titanium-dioxide filters sidestep this). If you do one thing for your skin, it's this.
Tretinoin (Retin-A)
Mostly mechanism / observationalA prescription TOPICAL retinoid (Retin-A, Renova) — the acid form of vitamin A and the gold-standard, best-evidenced topical treatment for photoaging and acne. Multiple double-blind RCTs show it reduces fine wrinkles, mottled hyperpigmentation, and roughness over months, with histologic increases in dermal collagen. Caveats: retinoid dermatitis (irritation, peeling, dryness), photosensitivity, and it is CONTRAINDICATED IN PREGNANCY. Prescription drug, not a supplement; distinct from weaker OTC 'retinol' cosmetics.
Azelaic Acid
Mostly mechanism / observationalA topical skincare acid applied to the skin for rosacea, acne, and uneven tone — unusual among 'cosmetic' actives because it has genuine drug-grade evidence. Azelaic acid is a naturally occurring dicarboxylic acid that is anti-inflammatory, antimicrobial, and a tyrosinase inhibitor. It is sold both as an over-the-counter cosmetic (around 10%) AND as a 15-20% prescription medication. The honest framing: the strongest, best-replicated evidence — including double-blind phase III trials and a Cochrane review that rated it high-quality for papulopustular rosacea — used the PRESCRIPTION strengths (15-20%), not the ~10% OTC cosmetic form. It also has solid evidence for acne and melasma. Head-to-head it is beaten for acne (by benzoyl peroxide + clindamycin) and tends to cause more local irritation (burning, stinging) than several comparators. For rosacea or persistent acne, the prescription form under a clinician is the evidence-based route.
Hydroquinone
Mostly mechanism / observationalThe long-standing gold-standard topical skin-lightening agent for melasma and hyperpigmentation — and now a regulated drug, not a cosmetic. Hydroquinone (HQ) competitively inhibits tyrosinase and is toxic to overactive pigment cells. The honest framing: it is the most rigorously studied and most effective topical depigmenter — a large pivotal RCT, a Cochrane review, and recent meta-analyses all use HQ 4% (and the 'Kligman' triple-combination with a retinoid + steroid) as the benchmark that newer agents are measured against and rarely beat. But it carries real liabilities: irritation, rebound pigmentation, and — with prolonged or high-strength use — a disfiguring complication called exogenous ochronosis. For these reasons it was pulled from US over-the-counter sale in 2020 (now prescription-only) and is restricted in the EU and elsewhere. Effective, but for monitored, time-limited medical use.
Explore: Best supplements for Skin, Hair & Beauty
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 11 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.